The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Cancer stem cells and chemoresistance: The smartest survives the raid
Open accessAbstract
Chemoresistant metastatic relapse of minimal residual disease plays a significant role for poor prognosis of cancer. Growing evidence supports a critical role of cancer stem cell (CSC) behind the mechanisms for this deadly disease. This review briefly introduces the basics of the conventional chemotherapies, updates the CSC theories, highlights the molecular and cellular mechanisms by which CSC smartly designs and utilizes multiple lines of self-defense to avoid being killed by chemotherapy, and concisely summarizes recent progress in studies on CSC-targeted therapies in the end, with the hope to help guide future research towards developing more effective therapeutic strategies to eradicate tumor cells in the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–303 of 303
Fu, J., Rodova, M., Roy, S. K., Sharma, J. P., Singh, K. P., Srivastava, R. K., & Shankar, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.018 · Cited by 148
Bao, B., Ahmad, A., Kong, D., Ali, S. S., Azmi, A. S., Li, Y., Banerjee, S., Padhyé, S., & Sarkar, F. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043726 · Cited by 145
Towards novel paradigms for cancer therapy
Pavet, V., Portal, M. M., Moulin, J.-F., Herbrecht, R., & Gronemeyer, H. (2010) · Oncogene · doi:10.1038/onc.2010.460 · Cited by 143
Epigenetic Regulation of SOX9 by the NF-κB Signaling Pathway in Pancreatic Cancer Stem Cells
Sun, L., Mathews, L., Cabarcas‐Petroski, S., Zhang, X., Yang, A., Zhang, Y., Young, M. R., Klarmann, K. D., Keller, J. R., & Farrar, W. L. (2013) · Stem Cells · doi:10.1002/stem.1394 · Cited by 143
Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist
Prud’homme, G. J., Glinka, Y., Toulina, A., Ace, O., Subramaniam, V., & Jothy, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013831 · Cited by 143
Chen, Y., Chen, K.-H., Huang, P., Chen, Y., Chiou, G.-Y., Lo, W., Tseng, L., Hsu, H.-S., Chang, K., & Chiou, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0504 · Cited by 138
Hypoxia-Regulated Delta-like 1 Homologue Enhances Cancer Cell Stemness and Tumorigenicity
Kim, Y., Lin, Q., Zelterman, D. A., & Yun, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1605 · Cited by 136
Kanwar, S. S., Yu, Y., Nautiyal, J., Patel, B. B., Padhyé, S., Sarkar, F. H., & Majumdar, A. P. N. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0336-y · Cited by 136
Yin, H., & Glass, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024080 · Cited by 135
Tsatmali, M., Walcott, E. C., & Crossin, K. L. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.087 · Cited by 133
Cancer stem cell: Fundamental experimental pathological concepts and updates
Islam, F., Qiao, B., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.02.002 · Cited by 131
Rodova, M., Fu, J., Nall, D., Srivastava, R. K., & Shankar, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046083 · Cited by 131
s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissuePreprint
Bai, L., & Rohrschneider, L. R. (2010) · Genes & Development · doi:10.1101/gad.1932810 · Cited by 130
Slow-Cycling Therapy-Resistant Cancer Cells
Moore, N., Houghton, J., & Lyle, S. R. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0477 · Cited by 129
Expression of Multidrug Resistance Genes in Normal and Cancer Stem Cells
Shervington, A. A., & Lu, C. (2008) · Cancer Investigation · doi:10.1080/07357900801904140 · Cited by 129
Kato, T., Natsume, A., Toda, H., Iwamizu, H., Sugita, T., Hachisu, R., Watanabe, R., Yuki, K., Motomura, K., Bankiewicz, K. S., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.88 · Cited by 127
The role of microRNAs in metastasis and epithelial-mesenchymal transition
Bracken, C. P., Gregory, P. A., Khew‐Goodall, Y., & Goodall, G. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8750-1 · Cited by 127
Hage, C., Rausch, V., Giese, N. A., Giese, T., Schönsiegel, F., Labsch, S., Nwaeburu, C. C., Mattern, J., Gladkich, J., & Herr, I. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.158 · Cited by 125
Nanta, R., Kumar, D., Meeker, D. G., Rodova, M., Veldhuizen, P. J. V., Shankar, S., & Srivastava, R. K. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.5 · Cited by 122
Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Yo, Y.-T., Lin, Y.-W., Wang, Y.-C., Balch, C., Huang, R., Chan, M. W. Y., Sytwu, H., Chen, C.-K., Chang, C., Nephew, K. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0002 · Cited by 122
Chen, Y., Chang, C.-J., Hsu, H., Chen, Y., Tai, L.-K., Tseng, L., Chiou, G., Chang, S., Kao, S., Chiou, S., et al. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.11.007 · Cited by 120
Liu, T., Xu, F., Du, X., Lai, D., Liu, T., Zhao, Y., Huang, Q. M., Jiang, L., Huang, W., Cheng, W., et al. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0426-5 · Cited by 120
CD44: a validated target for improved delivery of cancer therapeutics
Ghosh, S. C., Alpay, S. N., & Klostergaard, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.687374 · Cited by 118
Lee, T. K., Poon, R. T. P., Wo, J. Y. H., Ma, S., Guan, X., Myers, J. N., Altevogt, P., & Yuen, A. P. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0801 · Cited by 117
Schaeybroeck, S. V., Karaïskou, A., Kelly, D. M., Longley, D. B., Galligan, L., Cutsem, E. V., & Johnston, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0328 · Cited by 116
Triller, N., Korošec, P., Kern, I., Košnik, M., & Debeljak, A. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.019 · Cited by 115
Hsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S. (2011) · Cancer · doi:10.1002/cncr.25869 · Cited by 113
Integrins: Regulators of Tissue Function and Cancer Progression
Danen, E. H. J. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381756 · Cited by 113
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
Konecny, G. E., Venkatesan, N., Yang, G., Dering, J., Ginther, C., Finn, R. S., Rahmeh, M., Fejzo, M. S., Toft, D. O., Jiang, S.-W., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604278 · Cited by 112
Miyazaki, T., Pan, Y., Joshi, K., Purohit, D., Hu, B., Demir, H., Mazumder, S., Okabe, S., Yamori, T., Viapiano, M. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1795 · Cited by 111
Sabisz, M., & Składanowski, A. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9758 · Cited by 110
Piggott, L., Omidvar, N., Pérez, S. M., Eberl, M., & Clarkson, R. W. E. (2011) · Breast Cancer Research · doi:10.1186/bcr2945 · Cited by 110
Kim, M. R., Choi, H., Cho, K. B., Kim, H. S., & Kang, K. W. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01260.x · Cited by 109
Ashizawa, T., Miyata, H., Iizuka, A., Komiyama, M., Oshita, C., KUME, A., Nogami, M., Yagoto, M., Ito, I., Oishi, T., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1916 · Cited by 109
Lin, C., Wang, L., Wang, H., Yang, L., Guo, H., & Wang, X. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24553 · Cited by 108
Hashimoto, O., Shimizu, K., Semba, S., Chiba, S., Ku, Y., Yokozaki, H., & Hori, Y. (2011) · Pathobiology · doi:10.1159/000325538 · Cited by 108
What Makes Tumors Multidrug Resistant?
Borst, P., Jonkers, J., & Rottenberg, S. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4936 · Cited by 106
Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer
Kondratyev, M. K., Kreso, A., Hallett, R. M., Girgis-Gabardo, A., Barcelon, M., Ilieva, D., Ware, C., Majumder, P., & Hassell, J. A. (2011) · Oncogene · doi:10.1038/onc.2011.212 · Cited by 106
Aldehyde dehydrogenase 1A1—a new mediator of resistance to temozolomide in glioblastoma
Schäfer, A., Teufel, J., Ringel, F. A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos270 · Cited by 102
Sub-Sets of Cancer Stem Cells Differ Intrinsically in Their Patterns of Oxygen Metabolism
Gammon, L., Biddle, A., Heywood, H. K., Johannessen, A. C., & Mackenzie, I. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062493 · Cited by 100
Kendziorra, E., Ahlborn, K., Spitzner, M., Rave‐Fränk, M., Emons, G., Gaedcke, J., Krämer, F., Wolff, H. A., Becker, H., Beißbarth, T., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr222 · Cited by 100
Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line
Shi, M., Jiao, J., Lü, W., Ye, F., Ma, D., Dong, Q., & Xie, X. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0420-9 · Cited by 99
Serrano, D., Bleau, A., Fernandez‐Garcia, I., Fernández‐Marcelo, T., Iniesta, P., Ortíz-de-Solórzano, C., & Calvo, A. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-96 · Cited by 99
Induced pluripotent stem cells and reprogramming: seeing the science through the hype
Belmonte, J. C. I., Ellis, J., Hochedlinger, K., & Yamanaka, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2700 · Cited by 98
Guvenc, H., Pavlyukov, M. S., Joshi, K., Kurt, H., Banasavadi‐Siddegowda, Y., Mao, P., Hong, C. S., Yamada, R., Kwon, C., Bhasin, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0647 · Cited by 94
Wang, L., Guo, H., Yang, L., Dong, L., Lin, C., Zhang, J., Lin, P., & Wang, X. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1621-y · Cited by 93
Chefetz, I., Holmberg, J. C., Alvero, A. B., Visintin, I., & Mor, G. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16348 · Cited by 92
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatesha, V. A., Parsels, L. A., Parsels, J. D., Zhao, L., Zabludoff, S., Simeone, D. M., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2012) · Neoplasia · doi:10.1593/neo.12538 · Cited by 91
Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
Hellsten, R., Johansson, M., Dahlman, A., Sterner, O., & Bjartell, A. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022118 · Cited by 91
Capper, D., Gaiser, T., Hartmann, C. J., Habel, A., Mueller, W. C., Herold‐Mende, C. C., von Deimling, A., & Siegelin, M. D. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0494-3 · Cited by 90
Bélanger, A.-S., Tojcic, J., Harvey, M., & Guillemette, C. (2010) · BMC Molecular Biology · doi:10.1186/1471-2199-11-9 · Cited by 86
Ruff, P., Vorobiof, D., Jordaan, J. P., Demetriou, G. S., Moodley, S. D., Nosworthy, A. L., Werner, I. D., Raats, J., & Burgess, L. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0925-9 · Cited by 85
Concise Review: Cancer Stem Cells and Minimal Residual Disease
Ghiaur, G., Gerber, J. M., & Jones, R. J. (2011) · Stem Cells · doi:10.1002/stem.769 · Cited by 84
Sciuscio, D., Diserens, A., Dommelen, K. V., Martinet, D., Jones, G., Janzer, R.-C., Pollo, C., Hamou, M., Kaina, B., Stupp, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1931 · Cited by 84
Gunn, E. J., Williams, J. T., Huynh, D. T., Iannotti, M. J., Han, C., Barrios, F. J., Kendall, S. E., Glackin, C. A., Colby, D. A., & Kirshner, J. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.555891 · Cited by 84
Sokol, J. P., Neil, J. R., Schiemann, B. J., & Schiemann, W. P. (2005) · Breast Cancer Research · doi:10.1186/bcr1312 · Cited by 83
Kusunoki, S., Kato, K., Tabu, K., Inagaki, T., Okabe, H., Kaneda, H., Suga, S., Terao, Y., Taga, T., & Takeda, S. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.005 · Cited by 83
Allan, E. K., Holyoake, T. L., Craig, A. R., & Jørgensen, H. G. (2011) · Leukemia · doi:10.1038/leu.2011.55 · Cited by 81
Importance of ABCC1 for cancer therapy and prognosis
Kunická, T., & Souček, P. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.901348 · Cited by 78
The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma
Huynh, C., Poliseno, L., Segura, M. F., Medicherla, R. C., Haimovic, A., Menéndez, S., Shang, S., Pavlick, A. C., Shao, Y., Darvishian, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025264 · Cited by 76
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures
Carra, E., Barbieri, F., Marubbi, D., Pattarozzi, A., Favoni, R. E., Florio, T., & Daga, A. (2013) · Cell Cycle · doi:10.4161/cc.23372 · Cited by 75
Zhang, Y., Piao, B., Zhang, Y., Hua, B., Hou, W., Xu, W.-R., Qi, X., Zhu, X., Pei, Y., & Lin, H. (2010) · Medical Oncology · doi:10.1007/s12032-010-9721-y · Cited by 73
Masui, T., Ota, I., Yook, J. I., Mikami, S., Yane, K., Yamanaka, T., & Hosoi, H. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2225 · Cited by 73
Zalcberg, J. R., Xf, H., Slater, A., Parisot, J. P., El‐Osta, A., Kantharidis, P., St, C., & Parkin, J. D. (2000) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500394 · Cited by 73
Gieni, R. S., Ismail, I. H., Campbell, S., & Hendzel, M. J. (2011) · Cell Cycle · doi:10.4161/cc.10.6.14907 · Cited by 71
Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C. A., Lang, F. F., Aldape, K., Szymański, S., Fokt, I., Dasgupta, A., Madden, T. L., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0786-z · Cited by 71
HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
Newman, B. W., Liu, Y., Lee, H.-F., Sun, D., & Wang, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3600 · Cited by 70
Pollock, C. B., Koltai, H., Kapulnik, Y., Prandi, C., & Yarden, R. I. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1992-x · Cited by 70
Regulation of Inflammation by the NF-κB Pathway in Ovarian Cancer Stem Cells
Leizer, A. L., Alvero, A. B., Fu, H. H., Holmberg, J. C., Cheng, Y., Silasi, D., Rutherford, T., & Mor, G. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00914.x · Cited by 67
Role of uridine phosphorylase in the anabolism of 5-fluorouracil
Schwartz, P. M., Moir, R. D., Cm, H., Turek, P. J., & Handschumacher, R. E. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90737-3 · Cited by 66
Zhuang, W., Li, B.-Z., Long, L., Chen, L., Huang, Q., & Liang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.044 · Cited by 65
Principles of cytotoxic chemotherapy
Lind, M. (2008) · Medicine · doi:10.1016/j.mpmed.2007.10.003 · Cited by 65
Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ER-α Status
Harrison, H., Rogerson, L., Gregson, H. J., Brennan, K. R., Clarke, R. B., & Landberg, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2505 · Cited by 63
Houghton, J. A., & Houghton, P. J. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90013-5 · Cited by 62
Characterization of primary ovarian cancer cells in different culture systems
Lai (2010) · Oncology Reports · doi:10.3892/or_00000761 · Cited by 62
Robey, R. W., Shukla, S., Steadman, K., Obrzut, T., Finley, E. M., Ambudkar, S. V., & Bates, S. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0811 · Cited by 61
Principles of cytotoxic chemotherapy
Lind, M. (2011) · Medicine · doi:10.1016/j.mpmed.2011.09.009 · Cited by 60
Bhatia, P., Bernier, M., Sanghvi, M., Moaddel, R., Schwarting, R., Ramamoorthy, A., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.662726 · Cited by 58
Sumitomo, M., Asano, T., Asakuma, J., Asano, T., Horiguchi, A., & Hayakawa, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0948-03 · Cited by 57
Alvero, A. B., Montagna, M. K., Chen, R., Kim, K. H., Kyungjin, K., Visintin, I., Fu, H., Brown, D., & Mor, G. (2009) · Cancer · doi:10.1002/cncr.24397 · Cited by 55
Kishida, O., Miyazaki, Y., Murayama, Y., Ogasa, M., Miyazaki, T., Yamamoto, T., Watabe, K., Tsutsui, S., Kiyohara, T., Shimomura, I., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0959-y · Cited by 53
Cisplatin and TRAIL enhance breast cancer stem cell death
Reddy, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1085 · Cited by 49
Dong, Y., Han, Q., Zou, Y., et al. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1401-0 · Cited by 47
Jiang, L., Zhang, X., Du, P., & Zheng, J. (2011) · Chinese Journal of Cancer Research · doi:10.1007/s11670-011-0140-1 · Cited by 47
Kang, K. B., Zhu, C., Wong, Y. L., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.11.037 · Cited by 46
Maciejczyk, A., Jagoda, E., Wysocka, T., Matkowski, R., Győrffy, B., Lage, H., & Surowiak, P. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9449-9 · Cited by 44
An epigenetic mechanism for capecitabine resistance in mesothelioma
Kosuri, K. V., Wu, X., Wang, L., Villalona-Calero, M. A., & Otterson, G. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.095 · Cited by 44
Takehara, M., Hoshino, T., Namba, T., Yamakawa, N., & Mizushima, T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.012 · Cited by 43
Synthetic, Non-saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells
Patel, N. J., Karuturi, R., Al‐Horani, R. A., Baranwal, S., Patel, J., Desai, U. R., & Patel, B. B. (2014) · ACS Chemical Biology · doi:10.1021/cb500402f · Cited by 43
Deng, Y., Su, Q., Mo, J., Fu, X., Zhang, Y., & Lin, E. H. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.754458 · Cited by 42
Schaeybroeck, S. V., Kelly, D. M., Kyula, J., Stokesberry, S. A., Fennell, D. A., Johnston, P. G., & Longley, D. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6736 · Cited by 40
Liu, H., Han, D., Liu, Y., Hou, X., Wu, J., Li, H., Yang, J., Shen, C., Yang, G., Fu, C., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1034-x · Cited by 35
Styczyński, J., & Drewa, T. A. (2007) · Acta Biochimica Polonica · doi:10.18388/abp.2007_3140 · Cited by 34
Zhu, C., Cheng, K., Ouyang, N., Huang, L., Sun, Y., Constantinides, P. P., & Rigas, B. (2012) · Stem Cells · doi:10.1002/stem.1139 · Cited by 32
Li, T., Lu, H., Mukherjee, D., Lahiri, S. K., Shen, C., Yu, L., & Zhao, J. (2015) · Oncotarget · doi:10.18632/oncotarget.4077 · Cited by 29
Self-citationLee, Y.-R., Yü, D., Liang, Y.-C., Huang, K.-F., Chou, S., Chen, T., Lee, C.-C., Chen, C., Chiou, S., & Huang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056284 · Cited by 29
Rentala, S., Chintala, R., Guda, M., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.112 · Cited by 26
Farhana, L., Dawson, M. I., Das, J., et al. (2012) · Journal of Oncology · doi:10.1155/2012/796729 · Cited by 26
Koelling, T., Yeager, A., Hilton, A., et al. (1990) · Blood · doi:10.1182/blood.v76.6.1209.1209 · Cited by 23
Kishida, O., Miyazaki, Y., Murayama, Y., Ogasa, M., Miyazaki, T., Yamamoto, T., Watabe, K., Tsutsui, S., Kiyohara, T., Shimomura, I., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0904-0 · Cited by 23
Wu, C., Hung, J., & Wu, K. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05594.x · Cited by 22
Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation
Zhan, J., Wu, L., Chen, L., Yuan, Y., Xie, G., Sun, A.-M., Liu, Y., & Chen, Z.-X. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0020-1 · Cited by 17
Sun, Y., Zheng, S., Speirs, C. K., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.328 · Cited by 4
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
The Role of Nrf2 Activity in Cancer Development and Progression
Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 292
Metadata
- Authors
- Zhao, J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 160
- Pages
- 145-158
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2284683492
- Cited by
- 437
- References
- 303
- FWCI
- 20.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.